Literature DB >> 14871815

Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase.

Hiroyuki Nakamura1, Naoko Suenaga, Kaori Taniwaki, Hirokazu Matsuki, Kayoko Yonezawa, Masato Fujii, Yasunori Okada, Motoharu Seiki.   

Abstract

CD44 is a receptor for hyaluronan and mediates signaling that regulates complex cell behavior including cancer cell migration and invasion. Shedding of the extracellular portion of CD44 is the last step in the regulation of the molecule-releasing interaction between the ligand and cell. However, highly glycosylated forms of CD44 have hampered the identification of the exact cleavage sites for shedding and the responsible proteases. In this study, we found that expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) increased shedding of the 65-70 kDa CD44H (standard form) fragments and generated two additional smaller fragments. We purified the shed fragments and identified the cleaved sites by mass spectrometry. Specific antibodies that recognize the newly exposed COOH terminus by cleavage were prepared and used to analyze shedding at each site. Shedding of the 65-70 kDa fragments was inhibited by tissue inhibitor of metalloproteinase 3 (TIMP-3) but not by TIMP-1 and TIMP-2, suggesting involvement of a disintegrin and metalloproteinase (ADAM)-like proteases, although shedding is affected by MT1-MMP. Conversely, shedding of the two smaller fragments was inhibited by TIMP-2 and TIMP-3 but not TIMP-1, suggesting involvement of MT1-MMP itself. Shed fragments cleaved at these sites were also detected in human tumor tissues. Increased shedding at one of the MT1-MMP-sensitive sites was observed in the tumor compared with the surrounding normal tissue. However, no significant difference was observed with shedding by ADAM-like proteases. Thus, the cleavage sites for the shedding of CD44H were identified for the first time, and the results provide a basis for exploring the unknown biologic roles of shedding at different sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871815     DOI: 10.1158/0008-5472.can-03-3502

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Induction of CD44 cleavage in articular chondrocytes.

Authors:  Nobunori Takahashi; Cheryl B Knudson; Sai Thankamony; Wataru Ariyoshi; Liliana Mellor; Hee-Jeong Im; Warren Knudson
Journal:  Arthritis Rheum       Date:  2010-05

2.  Intracellular domain fragment of CD44 alters CD44 function in chondrocytes.

Authors:  Liliana Mellor; Cheryl B Knudson; Daisuke Hida; Emily B Askew; Warren Knudson
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 3.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

4.  Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma.

Authors:  Ying-Chi Ip; Siu-Tim Cheung; Ka-Ling Leung; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression.

Authors:  Cristhian J Ildefonso; Wesley S Bond; Azza R Al-Tawashi; Mary Y Hurwitz; Richard L Hurwitz
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

Review 6.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

7.  Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment.

Authors:  Erika L Spaeth; Adam M Labaff; Bryan P Toole; Ann Klopp; Michael Andreeff; Frank C Marini
Journal:  Cancer Res       Date:  2013-07-09       Impact factor: 12.701

8.  A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.

Authors:  Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2020-02-24       Impact factor: 12.531

Review 9.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 10.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.